PACE (PATHWAYS TO ANTIMICROBIAL CLINICAL EFFICACY)
DEAD

Serial Number

79400685

Owner

LIFEARC

Filing Date

Dec 12, 2023

Add to watchlist:

No watchlists yet
View on USPTO

PACE (PATHWAYS TO ANTIMICROBIAL CLINICAL EFFICACY) Trademark

Serial Number: 79400685

PACE (PATHWAYS TO ANTIMICROBIAL CLINICAL EFFICACY) is a trademark filed by LIFEARC on December 12, 2023. The trademark is classified under Class 36 (Insurance & Financial), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

LIFEARC (3 trademarks)

7th Floor, Lynton House,

Entity Type: 99

Trademark Details

Filing Date

December 12, 2023

Registration Date

Not Registered

Goods & Services

Promoting research in the field of human health and human diseases through the support and coordination of research projects conducted by universities, hospitals, research foundations and businesses; providing advisory, consultancy and information services in the field of commercialisation of products and services by identifying routes to market for research; compilation of scientific, medical and clinical information; maintenance, namely updating of information in databases in relation to medical and health research.

Scientific, medical and clinical research services, biotechnology research and analysis, biochemical research and analysis, biological research and analysis, clinical trials, data mining in relation to medical and health research, data security services in relation to medical and health research, data encryption services in relation to medical and health research, database design and development in relation to medical and health research, mathematical modelling in relation to medical and health research, bioinformatics, drug discovery services, laboratory research, computer programming and design services in relation to medical and health research; consultancy services relating to all of the foregoing; scientific research and development in the field of medical technology; research on the development and adaptation of health technology and health-related outcomes associated with implementation of health technology; clinical research services, namely, collection, calibration, analysis and reporting of data in connection with clinical trials; conducting clinical trials for diagnostic tests and for pharmaceutical preparations; providing temporary use of non-downloadable web-based computer software for data integration, exchange, and analysis in relation to medical and health research; providing biomedical and scientific information via a global internet web site related to the field of human health and human diseases; technology transfer services namely product design and development, research and development, product development in relation to medical and health research; antibody humanisation services, namely antibody engineering; biopharmaceutical development; biologic assay development; preclinical research; clinical research; clinical trials management; pharmacovigilance, namely monitoring the effects of medical drugs after they have been licensed for use.

Charitable fund raising; charitable collections; organisation of collections; provision of funding for research, education, prevention and treatment of illnesses and human diseases; financial grant services; provision of funding for charities; provision of funding for medical trials; provision of funding for educational and research posts; information and advisory services relating to all the aforesaid; technology transfer services, namely assisting technologies inventors secure appropriate funding to take development forward; technology transfer services, namely managing revenue from partnered or developed intellectual property; all of the aforesaid in relation to medical and health research.

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 19, 2026 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Mar 5, 2026 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 5, 2026 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 8, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 24, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 24, 2025 OPNR
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Mar 5, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Mar 5, 2025 ABN2
NEW REPRESENTATIVE AT IB RECEIVED
Feb 7, 2025 NREP
REFUSAL PROCESSED BY IB
Sep 9, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 19, 2024 RFCS
REFUSAL PROCESSED BY MPU
Aug 17, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 8, 2024 RFCR
NON-FINAL ACTION WRITTEN
Aug 7, 2024 CNRT
ASSIGNED TO EXAMINER
Jul 30, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 29, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 29, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 25, 2024 REPR